| Text of Recommendation | CMS should take steps to inform providers about the availability of buprenorphine combination products in Part D, which can minimize the risk of misuse and diversion. |
|---|---|
| Recommendation Number | 23-E-02-028.03 |
| Recommendation Status | Open |
| Significant Recommendation | No |
| Recommendation Questioned Costs | $0 |
| Recommendation Funds for Better Use | $0 |
| Submitting OIG | |
|---|---|
| Linked Report |